Patent Invalidity Heading To Supreme Court In April As Rx Firms Square Off In Microsoft Case
Executive Summary
Brand and generic drug manufacturers have squared off on opposite sides of a case to be taken up by the Supreme Court in April that could change the standard of proof required to show that a patent is invalid.
You may also be interested in...
Brand Pharma Gets "Clear And Convincing" Patent Win At The Supreme Court
Brand name and generic companies had taken opposite sides in a case in which Microsoft sought to lower the standard for invalidating a patent from "clear and convincing evidence" to "preponderance of the evidence."
Inequitable Conduct: Drug Industry Implores Federal Circuit To Revise Standard For Finding Deception In Patent Prosecution
The pharmaceutical industry has jumped at the opportunity to weigh in on a case that could change how courts determine whether patent owners deceived the U.S. Patent and Trademark Office in obtaining their patents
Supreme Court Loosens Rule On What Processes Can Be Patented
To the relief of the biotechnology industry, the court rules in the Bilski case that a process need not be tied to a machine or transform an article to be patented.